Observational studyResearch and practice in thrombosis and haemostasis2026
Plasma emicizumab concentrations and bleeding rates in children and adults with severe hemophilia A.
Observational study in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emicizumab has been in clinical use for less than 10 years. Real-world experience is still needed to guide its use for optimal safety, efficacy, and resource efficiency. Recent data suggest that conventional weight-based dosing may be excessive for many patients. More data on the correlation between bleeding events and plasma emicizumab concentation will help to clarify optimal dosing regimens. Objectives: To determine bleeding rates and their correlation with drug levels in patients without inhibitors using prophylactic emicizumab. Methods: We conducted an observational study in a large cohort of adult and pediatric persons with severe hemophilia A without inhibitors to determine the rate of bleeding events during emicizumab prophylaxis and the correlation between plasma emicizumab concentration and bleeding rates. Results: Among the 73 patients followed for a mean of 69.0 weeks, 47.9% had 0 treated bleeds and 80.8% had 0 spontaneous bleeds. The mean and median annualized treated bleed rates were 1.12 and 0.57, and the mean and median annualized joint bleed rates were 0.51 and 0. The mean factor VIII concentrate used to treat bleeds was 63.0 IU/kg/y per patient (median, 23.1 IU/kg/y). Steady-state plasma emicizumab concentration did not correlate with total or spontaneous annualized treated bleed rate and annualized joint bleed rate or with patient age at enrolment, body weight, or body mass index. Dose capping at 150 mg/wk did not result in lower emicizumab concentrations in the 9 patients with body weight >100 kg. Conclusion: Emicizumab provided highly effective prophylaxis in persons with severe hemophilia A across the age spectrum. The lack of correlation of bleed outcomes with plasma emicizumab concentration suggests that minimal effective drug concentrations should be reconsidered. Studies to rationalize and personalize therapy should be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.